SciHub
文献互助
期刊查询
一搜即达
科研导航
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!
安静元槐
Lv4
480 积分
2023-07-03 加入
最近求助
最近应助
互助留言
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
11天前
已完结
The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies
1个月前
已完结
The CDK4/6 inhibitor revolution — a game-changing era for breast cancer treatment
1个月前
已完结
Cell Cycle Regulation in Treatment of Breast Cancer
2个月前
已完结
TACC3: a multi-functional protein promoting cancer cell survival and aggressiveness
3个月前
已完结
The centrosomal protein TACC3 controls paclitaxel sensitivity by modulating a premature senescence program
3个月前
已完结
The centrosomal protein TACC3 controls paclitaxel sensitivity by modulating a premature senescence program
3个月前
已关闭
Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: MAINTAIN Trial
4个月前
已完结
A mechanically active heterotypic E-cadherin/N-cadherin adhesion enables fibroblasts to drive cancer cell invasion
4个月前
已完结
Treating cancer with selective CDK4/6 inhibitors
4个月前
已完结
没有进行任何应助
dn等待时间久【积分已退回】
3个月前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论